Download presentation
Presentation is loading. Please wait.
Published byRoderick Lindsey Modified over 8 years ago
1
Boston Children’s Hospital Alan B. Retik, M.D. Professor of Surgery, Harvard Medical School Department of Urology, Boston Children’s Hospital How To Investigate the First Episode of UTI. A New Debate
2
2011 AAP Guidelines Evaluation of the Infant with Febrile UTI First revision of AAP guidelines since 1999 Takes into account newer data regarding diagnosis and treatment of UTI, imaging evaluation, and use of antibiotics Panel comprised of pediatricians, infectious disease specialists, radiologists, and 1 pediatric urologist
3
2011 AAP Guidelines Evaluation of the Infant with Febrile UTI Seven Recommendations – –Diagnosis of UTI 1) 1)If clinical suspicion of UTI, obtain urine prior to antibiotics via suprapubic tap or catheter 2) 2)In reasonably well infants, assess risk of UTI based on risk factors (gender, race, age, temp, fever duration, and other source) - low risk infant can be considered for observation 3) 3)UTI diagnosis requires both a urinalysis AND a positive culture (>50,000 cfu)
4
Seven Recommendations – –UTI treatment 4) Oral or parenteral treatment with appropriate antibiotics for 7-14 days; take local sensitivity patterns into account if possible; adjust treatment according to the sensitivity profile of the isolated organism 2011 AAP Guidelines Evaluation of the Infant with Febrile UTI
5
Seven Recommendations – –Post-UTI evaluation 5) Infants with febrile UTI should have a renal and bladder ultrasound 6) VCUG should be deferred until the SECOND febrile UTI, unless the ultrasound is abnormal – –Post-UTI management 7) Parents should be instructed to seek prompt evaluation for future febrile illnesses 2011 AAP Guidelines Evaluation of the Infant with Febrile UTI
6
Rationale for the change in recommendation of VCUG timing after febrile UTI – –Most infants will not have recurrent UTI – –Most infants do not have severe anatomic abnormalities amenable to surgical correction – –Identification of VUR in infants is of unproven clinical benefit – –Most infants with VUR have low-grade VUR, which will resolve spontaneously in most cases – –Even if VUR is identified, antibiotic prophylaxis has not been shown to be effective in preventing VUR recurrence 2011 AAP Guidelines Evaluation of the Infant with Febrile UTI
7
Data for the meta-analysis to support these conclusions were highly heterogeneous. Included: –some children without febrile infections –some children without VUR –UTI’s diagnosed via non-catheterized specimens Recent published Swedish Reflux Study which showed a strong effect of antibiotic prophylaxis in preventing UTI was not included
8
NIH-funded RIVUR multicenter trial comparing antibiotic prophylaxis with placebo not taken into account CPG also implies that finding VUR by VCUG is not warranted because very few infants will have severe (grade 5) reflux However, lower grades of reflux can cause recurrent pyelonephritis and renal scarring
9
All grades of VUR can only be detected by VCUG VUR is routinely missed by ultrasound Only one-third of patients with grade 4 and 5 reflux have abnormal ultrasounds Anti-reflux surgery in a randomized trial shown to reduce recurrent febrile UTI in children with grade 3 and 4 reflux.
10
CPG states that the increase in scarring from recurrent UTI is “ insufficient to justify subjecting all infants with an initial febrile UTI to VCUG.”
11
Relationship between renal scarring and number of bouts of pyelonephritis. Adapted from Jodal et al.
13
Of 1533 articles – 325 full-text articles reviewed – 33 studies met inclusion criteria Children with an initial UTI – 57% had changes consistent with acute pyelonephritis on the acute phase DMSA scan – 15% had renal scarring on follow up DMSA scan
14
Children with reflux more likely to develop pyelonephritis and renal scarring Children with VUR grades III or higher more likely to develop scarring
15
VCUG Procedure Anxieties from physicians and patients re. discomfort and radiation With experienced team, discomfort of VCUG similar to immunization With current digital pulsed fluorsocopy radiation dose minimal-equivalent to 2 weeks of background radiation or a cross- country round-trip plane flight.
16
>50% of parents classified experience as equivalent or better than PE, immunization, or US Most are satisfied with ability of child to tolerate the procedure and considered the experience better than expected
17
Children’s Hospital Boston, Departments of Urology, Radiology and Nephrology and Urology Section of the AAP do not feel there is sufficient evidence to change our current recommendations Renal ultrasound and VCUG after first febrile UTI Deferring the VCUG until after the second febrile UTI is an option in selected patients (low risk, reliable families)
22
Bottom-up and Top-down Approaches Top-down Approach – Missed 33% of high grade reflux – Cost $82.9 million vs. $59.2 million for the Bottom-up Approach – Radiation dose 0.72 mSv (vs. 0.06 mSv for Bottom-up Approach)
23
Therapy for VUR Medical management – –Low-dose antibiotic prophylaxis for prevention of recurrent UTI – –Stems largely from uncontrolled series’ in 1970’s – –Based on several assumptions Most VUR, especially Grade I-III, resolves Renal damage is rare in the absence of infection Long-term antimicrobial prophylaxis is safe Long-term antimicrobial prophylaxis is effective
24
Therapy for VUR Medical management – –Amoxicillin Agent of choice for newborns – –Trimethoprim/sulfamethoxazole Widely used, well-tolerated, convenient – –Nitrofurantoin Low rate of resistance Liquid form expensive, tastes terrible – –Cephalosporin Higher rate of resistance?
25
Therapy for VUR – Controversy Recent publications have challenged conventional wisdom regarding efficacy of antibiotic prophylaxis Some practitioners are reconsidering medical management of VUR BUT Lets not be too hasty!!
26
Recent studies evaluating antimicrobial prophylaxis for VUR/UTI StudyBlinded ? AgesVUR Grade UTI Dx F/U time ABXNo ABXRR (95% CI) Number (%) of children with UTI Garin (Pediatrics, 2006)No1 mo– 18 yr I-IIICath or voided 12 mo13/55 (24%)12/58 (21%)1.1 (0.6- 2.3) Roussey (J Urol, 2008)No1-36 mo I-IIIBag18 mo18/103 (17%)32/122 (26%)0.7 (0.4- 1.1) Pennesi (Pediatrics, 2008) No0-30 mo II-IVBag24 mo18/50 (36%)15/50 (30%)1.2 (0.7- 2.1) Montini (Pediatrics, 2008) No2-84 mo I-IIIBag12 mo10/82 (12%)9/46 (20%)0.62 (0.3- 1.4) Craig (NEJM, 2009)Yes0-18 yr0-VCath or voided 12 mo36/288 (13%)55/288 (19%)0.65 (0.4-.96) Swedish Trial (Brandstrom J Urol 2010) No12-24 mos III-IVBag24 mos8/43 (19%) (girls only) 24/42 (57%) (girls only) 0.33 (0.17- 0.64)
27
THE RIVUR STUDY Randomized Intervention for children with Vesico- Ureteral Reflux (RIVUR) NIDDK Randomized trial of Bactrim vs. placebo Males and females, age 6 wks-5 years First or second febrile/symptomatic UTI Grade I-IV VUR on VCUG 2 year follow-up Primary Endpoint: Recurrent UTI Results Expected in ~2014
28
Return to the 2011 AAP Guidelines Seven Recommendations – –Post-UTI evaluation 6) VCUG should be deferred until the SECOND febrile UTI, unless the ultrasound is abnormal The CPG assumes that prophylaxis is NOT effective – but the final word on prophylaxis is not yet written My feeling is that there is probably a subset in whom prophylaxis is beneficial
29
The jury is still out! We still recommend prophylaxis for most patients with VUR Especially: Febrile UTI High grade VUR Renal scarring VUR and antibiotics – Take Home Message
30
Therapy - Surgery Anti-reflux Surgery - generally reserved for patients who: – –Have breakthrough UTI’s – –Have VUR that does not resolve after years of surveillance – –Are unable/unwilling to comply with prophylaxis – –Have high-grade VUR that is unlikely to resolve spontaneously
31
Therapy - Surgery Surgical management – Open surgery Reconstruct the ureterovesical junction with anti-reflux mechanism Intravesical versus extravesical approach 1-3 day hospital stay 95%+ success rate (resolution of VUR)
32
Therapy - Surgery Surgical management –Endoscopic treatment Injection of bulking agent at uretero-vesical junction → → Dextranomer/hyaluronic acid copolymer → → Marketed as Deflux® → → Approved by FDA in 2001 Outpatient procedure No incision
33
Therapy - Surgery Surgical management –Endoscopic treatment Less effective in higher-grade VUR Overall, 75-90% success rate May need more than one procedure to achieve success injection Risk of recurrent VUR despite initial success → → May reduce long-term success rate to ~50%
34
Current Treatment Remains Traditional Imaging evaluation, including cystogram, for most children with febrile UTI – –AAP guidelines officially sanction waiting until a second febrile UTI to do a VCUG – –This is controversial Antibiotic prophylaxis for children with VUR Surgery reserved for children with breakthrough UTI or persistent VUR But All of these are up for discussion!!!
35
Thank You!
36
Contact Us For questions, please contact me at alan.retik@childrens.harvard.edu For more information, visit Boston Children’s Hospital at booth #15 36
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.